Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Amarin Corporation plc AMRN

Healthcare Biotechnology
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult... see more

Recent & Breaking News (NDAQ:AMRN)

Investigators to Present New REDUCE-IT Subanalysis of VASCEPA®/VAZKEPA® (icosapent ethyl) in Patients With and Without Coronary Artery Disease History and Mechanistic Data on Eicosapentaenoic Acid (EPA) at the American Heart Association's (AHA) Annual Scientific Sessions

GlobeNewswire 11 days ago

Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire October 30, 2024

Amarin Announces Two Upcoming Investor Events

GlobeNewswire October 1, 2024

Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting

GlobeNewswire September 9, 2024

Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress

GlobeNewswire August 22, 2024

Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire July 31, 2024

Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal

GlobeNewswire July 17, 2024

Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024

GlobeNewswire July 17, 2024

Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)

GlobeNewswire July 8, 2024

Amarin Board of Directors Announces CEO Transition

GlobeNewswire June 4, 2024

 Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.

GlobeNewswire May 28, 2024

Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference

GlobeNewswire May 6, 2024

 Amarin Reports First Quarter 2024 Business Update and Financial Results

GlobeNewswire May 1, 2024

Amarin Applauds HealthyWomen's Citizen's Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event

GlobeNewswire April 24, 2024

Amarin Announces Results of Annual General Meeting of Shareholders

GlobeNewswire April 22, 2024

Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024

GlobeNewswire April 15, 2024

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24

GlobeNewswire April 8, 2024

New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

Canada NewsWire April 8, 2024

New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

GlobeNewswire April 6, 2024

Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe

GlobeNewswire April 3, 2024